IFNG and hemophagocytic syndrome: Clinical evidence supports the substantial amelioration of symptoms, disease progression, and enhanced survival rates in EBV-HLH patients following emapalumab treatment.[10] Nevertheless, some patients developed infections during emapalumab administration aimed at IFN-γ blockade, necessitating resolution through supportive antimicrobial interventions as well as discontinuation of etoposide and dexamethasone.